PolyPeptide Group AG - Asset Resilience Ratio

Latest as of June 2025: 9.92%

PolyPeptide Group AG (PPGN) has an Asset Resilience Ratio of 9.92% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CHF76.69 Million

≈ $96.96 Million USD Cash + Short-term Investments

Total Assets

CHF773.07 Million

≈ $977.37 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how PolyPeptide Group AG's Asset Resilience Ratio has changed over time. Check PolyPeptide Group AG PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down PolyPeptide Group AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PPGN company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF76.69 Million	9.92%
Short-term Investments	CHF0.00	0%
Total Liquid Assets	CHF76.69 Million	9.92%

Asset Resilience Insights

Limited Liquidity: PolyPeptide Group AG maintains only 9.92% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

PolyPeptide Group AG Industry Peers by Asset Resilience Ratio

Compare PolyPeptide Group AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Takeda Pharmaceutical Company Limited F:TKDA	Drug Manufacturers - Specialty & Generic	0.69%
Sandoz Group AG SW:SDZ	Drug Manufacturers - Specialty & Generic	7.89%
Viatris Inc NASDAQ:VTRS	Drug Manufacturers - Specialty & Generic	1.62%
China Resources Sanjiu Medical & Pharmaceutical Co Ltd SHE:000999	Drug Manufacturers - Specialty & Generic	5.22%
Humanwell Healthcare Group Co Ltd SHG:600079	Drug Manufacturers - Specialty & Generic	2.75%
Chengdu Kanghong Pharmaceuticals Group Co Ltd SHE:002773	Drug Manufacturers - Specialty & Generic	4.31%
Regencell Bioscience Holdings Ltd NASDAQ:RGC	Drug Manufacturers - Specialty & Generic	43.05%
Avadel Pharmaceuticals PLC NASDAQ:AVDL	Drug Manufacturers - Specialty & Generic	5.90%

Annual Asset Resilience Ratio for PolyPeptide Group AG (2018–2024)

The table below shows the annual Asset Resilience Ratio data for PolyPeptide Group AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	9.02%	CHF68.28 Million ≈ $86.32 Million	CHF756.58 Million ≈ $956.52 Million	-4.86pp
2023-12-31	13.89%	CHF95.71 Million ≈ $121.00 Million	CHF689.09 Million ≈ $871.19 Million	+7.37pp
2022-12-31	6.52%	CHF37.53 Million ≈ $47.45 Million	CHF575.78 Million ≈ $727.94 Million	-16.39pp
2021-12-31	22.91%	CHF136.30 Million ≈ $172.32 Million	CHF595.04 Million ≈ $752.29 Million	+18.33pp
2020-12-31	4.58%	CHF17.21 Million ≈ $21.76 Million	CHF375.98 Million ≈ $475.33 Million	-1.16pp
2019-12-31	5.74%	CHF17.51 Million ≈ $22.13 Million	CHF305.14 Million ≈ $385.78 Million	+2.20pp
2018-12-31	3.54%	CHF10.04 Million ≈ $12.69 Million	CHF283.83 Million ≈ $358.83 Million	--

pp = percentage points

About PolyPeptide Group AG

SW:PPGN Switzerland Drug Manufacturers - Specialty & Generic

Market Cap

$2.06 Billion

CHF1.63 Billion CHF

Market Cap Rank

#9958 Global

#125 in Switzerland

Share Price

CHF49.35

Change (1 day)

-0.10%

52-Week Range

CHF20.50 - CHF49.40

All Time High

CHF143.30